Brean Capital set a $14.00 target price on Trevena Inc. (NASDAQ:TRVN) in a report published on Thursday morning. The brokerage currently has a a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. FBR & Co reiterated a buy rating and issued a $13.00 price target on shares of Trevena in a report on Thursday, August 4th. Cowen and Company reiterated a buy rating and issued a $13.00 price target on shares of Trevena in a report on Friday, August 5th. Zacks Investment Research upgraded Trevena from a sell rating to a hold rating in a report on Wednesday, July 20th. Jefferies Group reiterated a buy rating on shares of Trevena in a report on Friday, August 5th. Finally, TheStreet lowered Trevena from a hold rating to a sell rating in a report on Friday, June 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $14.30.

Trevena (NASDAQ:TRVN) opened at 7.04 on Thursday. The firm’s market cap is $367.33 million. The firm’s 50 day moving average price is $6.94 and its 200 day moving average price is $7.30. Trevena has a 52-week low of $5.58 and a 52-week high of $13.10.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.01. Trevena had a negative return on equity of 45.01% and a negative net margin of 841.00%. Equities research analysts anticipate that Trevena will post ($1.55) EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of TRVN. FMR LLC raised its position in Trevena by 2.2% in the second quarter. FMR LLC now owns 7,753,948 shares of the biopharmaceutical company’s stock worth $48,850,000 after buying an additional 168,765 shares during the last quarter. Wellington Management Group LLP raised its position in Trevena by 47.0% in the first quarter. Wellington Management Group LLP now owns 5,714,773 shares of the biopharmaceutical company’s stock worth $47,262,000 after buying an additional 1,827,970 shares during the last quarter. BlackRock Fund Advisors raised its position in Trevena by 23.6% in the second quarter. BlackRock Fund Advisors now owns 1,834,099 shares of the biopharmaceutical company’s stock worth $11,555,000 after buying an additional 350,089 shares during the last quarter. Vanguard Group Inc. raised its position in Trevena by 12.5% in the second quarter. Vanguard Group Inc. now owns 1,381,542 shares of the biopharmaceutical company’s stock worth $8,703,000 after buying an additional 153,378 shares during the last quarter. Finally, Vivo Capital LLC bought a new position in Trevena during the first quarter worth approximately $9,924,000. 75.43% of the stock is owned by hedge funds and other institutional investors.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.